CEO: PAH Franchise Still Strong
UTHR Forging Ahead on Oral Treprostinil NDA Despite Miss
By Jennifer Boggs
Thursday, August 25, 2011
Investors of United Therapeutics Corp. experienced a bit of déjà vu Wednesday as shares took a tumble on disappointing data from a Phase III study testing oral treprostinil on top of background therapy in patients with pulmonary arterial hypertension (PAH).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.